UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 29, 2013

PDL BioPharma, Inc.

(Exact name of Company as specified in its charter)

000-19756
(Commission File Number)

Delaware	94-3023969
(State or Other Jurisdiction of Incorporation)	(I.R.S. Employer Identification No.)

932 Southwood Boulevard
Incline Village, Nevada 89451
(Address of principal executive offices, with zip code)

(775) 832-8500
(Company's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01 Regulation FD Disclosure.

On April 29, 2013, PDL BioPharma, Inc. (the Company) will distribute to analysts, at their request, a list of the Company's supplementary protection certificates and the underlying patents. This information is publicly available, but not in a consolidated format as is being distributed. A copy of the list is attached hereto at Exhibit 99.1.

Limitation of Incorporation by Reference

In accordance with General Instruction B.2. of Form 8-K, the information in this report, including the exhibit, is furnished pursuant to Item 7.01 and shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.

Item 9.01 Financial Statements and Exhibits.

Exhibit No.	Description
99.1	SPC List

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDL BIOPHARMA, INC.
(Company)

By: /s/ John P. McLaughlin
John P. McLaughlin
President, Chief Executive Officer and
Acting Chief Financial Officer

Dated: April 29, 2013

EXHIBIT INDEX

Exhibit No.	Description
99.1	SPC List

PDL BioPharma, Inc.
SPC Status Report

Country	Drug	Underlying Patent No.	SPC App. No.
Austria	HERCEPTIN® (Trastuzumab)	E133452	SZ36/2000
Belgium	HERCEPTIN® (Trastuzumab)	EP0451216	2000C/026
Germany	HERCEPTIN® (Trastuzumab)	68925536.5	10075038.9
Denmark	HERCEPTIN® (Trastuzumab)	PR174317	CA 2003 00007
Spain	HERCEPTIN® (Trastuzumab)	2081974T3	C200000026
Finland	HERCEPTIN® (Trastuzumab)	FI108797	L2002 0008
France	HERCEPTIN® (Trastuzumab)	EP0451216	00C0035
Great Britain	HERCEPTIN® (Trastuzumab)	GB0451216	SPC/GB00/032
Greece	HERCEPTIN® (Trastuzumab)	1001050	20000800025
Ireland	HERCEPTIN® (Trastuzumab)	82755	2003/006
Italy	HERCEPTIN® (Trastuzumab)	EP0451216	UB2000CCP708
Luxembourg	HERCEPTIN® (Trastuzumab)	EP0451216	90676
Netherlands	HERCEPTIN® (Trastuzumab)	EP0451216	300023
Norway	HERCEPTIN® (Trastuzumab)	310473	SPC/NO2001024
Portugal	HERCEPTIN® (Trastuzumab)	PT 92758	79
Sweden	HERCEPTIN® (Trastuzumab)	SE0451216	0090024-1
Austria	XOLAIR® (Omalizumab)	E133452	SZ42/2005
Belgium	XOLAIR® (Omalizumab)	EP0451216	2005C/038
Switzerland	XOLAIR® (Omalizumab)	EP0451216	C00451216/04
Germany	XOLAIR® (Omalizumab)	68925536.5	122005000057.40
Denmark	XOLAIR® (Omalizumab)	PR174317	CA 2005 00051
Spain	XOLAIR® (Omalizumab)	2081974T3	C200500046
Finland	XOLAIR® (Omalizumab)	FI108797	L20050028
France	XOLAIR® (Omalizumab)	EP0451216	05C0046
Great Britain	XOLAIR® (Omalizumab)	GB0451216	SPC/GB05/052
Hungary	XOLAIR® (Omalizumab)	211174	S0500022
Ireland	XOLAIR® (Omalizumab)	82755	2005/031
Italy	XOLAIR® (Omalizumab)	EP0451216	UB2006CCP903
Luxembourg	XOLAIR® (Omalizumab)	EP0451216	91208
Netherlands	XOLAIR® (Omalizumab)	EP0451216	300213
Norway	XOLAIR® (Omalizumab)	310473	SPC/NO2005026
Portugal	XOLAIR® (Omalizumab)	PT 92758	212
Sweden	XOLAIR® (Omalizumab)	SE0451216	0590038-6
Slovenia	XOLAIR® (Omalizumab)	SI 8912489	C-200640004
Austria	AVASTIN® (Bevacizumab)	E133452	SZ 6/2005
Belgium	AVASTIN® (Bevacizumab)	EP0451216	2005C/004
Switzerland	AVASTIN® (Bevacizumab)	EP0451216	C00451216/03
Germany	AVASTIN® (Bevacizumab)	68925536.5	12 2005 000 007.8

PDL BioPharma, Inc.
SPC Status Report

Country	Drug	Underlying Patent No.	SPC App. No.
Denmark	AVASTIN® (Bevacizumab)	PR174317	CA 2005 00006
Spain	AVASTIN® (Bevacizumab)	2081974T3	C200500004
Finland	AVASTIN® (Bevacizumab)	FI108797	L20050004
France	AVASTIN® (Bevacizumab)	EP0451216	05C0004
Great Britain	AVASTIN® (Bevacizumab)	GB0451216	SPC/GB05/009
Hungary	AVASTIN® (Bevacizumab)	211174	S0500005
Ireland	AVASTIN® (Bevacizumab)	82755	2005/007
Italy	AVASTIN® (Bevacizumab)	EP0451216	CU-B2005CCP865
Luxembourg	AVASTIN® (Bevacizumab)	EP0451216	91 139
Netherlands	AVASTIN® (Bevacizumab)	EP0451216	300173
Norway	AVASTIN® (Bevacizumab)	310473	SPC/NO2005005
Portugal	AVASTIN® (Bevacizumab)	PT 92758	188
Sweden	AVASTIN® (Bevacizumab)	SE0451216	0590004-8
Slovenia	AVASTIN® (Bevacizumab)	SI 8912489	C-200540007
Austria	TYSABRI® (natalizumab)	E133452	SZ26/2006
Belgium	TYSABRI® (natalizumab)	EP0451216	2006C/024
Germany	TYSABRI® (natalizumab)	68925536.5	122006000036.4
Denmark	TYSABRI® (natalizumab)	PR174317	CA 200600022
Spain	TYSABRI® (natalizumab)	2081974T3	C200600026
Finland	TYSABRI® (natalizumab)	FI108797	L20060010
France	TYSABRI® (natalizumab)	EP0451216	06C0028
Great Britain	TYSABRI® (natalizumab)	GB0451216	SPC/GB/06/027
Hungary	TYSABRI® (natalizumab)	211174	S0600007
Ireland	TYSABRI® (natalizumab)	82755	2006/027
Italy	TYSABRI® (natalizumab)	EP0451216	C-UB2006CCP929
Luxembourg	TYSABRI® (natalizumab)	EP0451216	91272
Netherlands	TYSABRI® (natalizumab)	EP0451216	300239
Norway	TYSABRI® (natalizumab)	310473	SPC/NO2006009
Portugal	TYSABRI® (natalizumab)	PT 92758	235
Sweden	TYSABRI® (natalizumab)	SE0451216	0690023-7
Slovenia	TYSABRI® (natalizumab)	SI 8912489	C-200640013
Switzerland	TYSABRI® (natalizumab)	EP0451216	C00451216/05
Austria	LUCENTIS® (Ranibizumab)	E133452	SZ36/2007
Belgium	LUCENTIS® (Ranibizumab)	EP0451216	2007C/030
Bulgaria	LUCENTIS® (Ranibizumab)	BG61095	07/041
Germany	LUCENTIS® (Ranibizumab)	68925536.5	122007000037.5
Denmark	LUCENTIS® (Ranibizumab)	PR174317	CA 2007 00029
Spain	LUCENTIS® (Ranibizumab)	2081974T3	C200700020

PDL BioPharma, Inc.
SPC Status Report

Country	Drug	Underlying Patent No.	SPC App. No.
Finland	LUCENTIS® (Ranibizumab)	FI108797	L20070013
France	LUCENTIS® (Ranibizumab)	EP0451216	07C0029
Great Britain	LUCENTIS® (Ranibizumab)	GB0451216	SPC/GB07/033
Hungary	LUCENTIS® (Ranibizumab)	211174	S070003
Ireland	LUCENTIS® (Ranibizumab)	82755	2007/019
Italy	LUCENTIS® (Ranibizumab)	EP0451216	UB2007CCP969
Luxembourg	LUCENTIS® (Ranibizumab)	EP0451216	91333
Netherlands	LUCENTIS® (Ranibizumab)	EP0451216	300279
Norway	LUCENTIS® (Ranibizumab)	310473	SPC/NO2007006
Portugal	LUCENTIS® (Ranibizumab)	PT 92758	269
Sweden	LUCENTIS® (Ranibizumab)	SE0451216	0790030-1
Slovenia	LUCENTIS® (Ranibizumab)	SI 8912489	C-200740008